Premium
Combination therapy with GH and cyproterone acetate does not improve final height in boys with non‐GH‐deficient short stature
Author(s) -
Kawai Masahiko,
Momoi Toru,
Yorifuji Tohru,
Muroi Junko,
Yamanaka Chutaro,
Sasaki Hiroshi,
Furusho Kenshi
Publication year - 1998
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1046/j.1365-2265.1998.00348.x
Subject(s) - cyproterone acetate , short stature , medicine , endocrinology , idiopathic short stature , cyproterone , bone age , dwarfism , growth hormone , biology , androgen , hormone , biochemistry , gene
BACKGROUND AND OBJECTIVE Recently, we reported that GH therapy without gonadal suppression (GS) decreased the final height of boys with non‐GH‐ deficient short stature by decreasing the height standard deviation score (SDS) for bone age (BA) during puberty. Combination therapy with GH and GS has been reported to suppress bone maturation and improve final height in some cases. We evaluated the effects of combination therapy with GH and GS using cyproterone acetate on the final height of boys with non‐GH‐deficient short stature. PATIENTS Fifty nine boys with non‐GH deficient short stature were observed retrospectively until they reached their final height. The boys were divided into 3 groups: Group A consisted of 26 boys who were not treated with GH, group B consisted of 13 boys who were treated with GH alone, and group C consisted of 20 boys who were treated with combination therapy with GH and GS using cyproterone acetate. At the start of observation, the height SDS for BA and projected height were matched among these three groups. RESULTS The mean ± SDS of the final height for groups A, B, and C were 162.7 ± 5.3 cm, 155.4 ± 4.9 cm, and 161.9 ± 3.2 cm, respectively. GH therapy did not affect the height SDS for BA during the prepubertal period. GH therapy without GS decreased the height SDS for BA during puberty in group B. Combination therapy with GH and cyproterone acetate increased the height SDS for BA between 12 and 14 years BA in group C. However, after GS therapy was discontinued at 14 years BA, the height SDS for BA gradually decreased and eventually reached the same value as that in group A. CONCLUSIONS GH therapy during the prepubertal period did not improve the final height of boys with non‐GH‐deficient short stature. GH therapy without GS decreased pubertal height gain, resulting in reduced final height. Combination therapy with GH and GS using cyproterone acetate decelerated the bone maturation during puberty which might be accelerated by GH therapy, but did not improve the final height which might have been attained without treatment.